So because only the 2-full-dose trial had large enough N, that's the one that's approved, so people will be given what is most likely 60% protection even though

So because only the 2-full-dose trial had large enough N, that's the one that's approved, so people will be given what is most likely 60% protection even though it's possible, likely even, that if the person administering the vaccine simply doesn't inject the whole first dose - the protection will be higher? What will happen when the 0.5+1 dose trials are finished? Will the dosage recommendation simply be changed then?